Seminars in Oncology

Papers
(The H4-Index of Seminars in Oncology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer71
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer62
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis31
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis31
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment26
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance22
Masthead22
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review20
Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance20
Table of Contents20
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics19
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans19
Role of neoadjuvant pembrolizumab in advanced melanoma17
Editorial Board16
Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study15
Military exposures and lung cancer in United States Veterans15
0.056676149368286